Vaccination prior to ADT significantly improved antitumor responses, mediated in part by increased infiltration of CD8+T cells following ADT. Targeting MDSC recruitment following ADT further enhanced antitumor responses. These findings suggest logical directions for future clinical trials to improve the efficacy of prostate cancer vaccines.

7 months ago

Journal

AR (Androgen receptor) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CXCR2 (Chemokine (C-X-C motif) receptor 2)

AR expression

MVI-118

8ms

NCI-2019-07273: pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer (clinicaltrials.gov)

P2, N=60, Recruiting, University of Wisconsin, Madison | Trial completion date: Dec 2025 --> Oct 2026 | Trial primary completion date: Mar 2024 --> Jan 2025

8 months ago

Trial completion date • Trial primary completion date • Metastases

Keytruda (pembrolizumab) • MVI-118 • MVI-816

12ms

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer (clinicaltrials.gov)

P1/2, N=60, Recruiting, University of Wisconsin, Madison | N=39 --> 60 | Trial completion date: Apr 2025 --> Dec 2028 | Trial primary completion date: Apr 2025 --> Dec 2026

12 months ago

Enrollment change • Trial completion date • Trial primary completion date • Checkpoint inhibition • Checkpoint block

CD8 (cluster of differentiation 8)

Opdivo (nivolumab) • Libtayo (cemiplimab-rwlc) • Firmagon (degarelix) • fianlimab (REGN3767) • MVI-118

1year

NCI-2019-07273: pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer (clinicaltrials.gov)

P2, N=60, Recruiting, University of Wisconsin, Madison | Trial primary completion date: Dec 2023 --> Mar 2024

1 year ago

Trial primary completion date

Keytruda (pembrolizumab) • MVI-118 • MVI-816